Sildenafil oral spray - Aspargo Laboratories
Alternative Names: ASP-001; ASP-002; BANDOLLatest Information Update: 01 Aug 2024
At a glance
- Originator Farmalider
- Developer Aspargo Laboratories
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Erectile dysfunction
Most Recent Events
- 31 Jul 2024 In July 2024, Aspargo Labs plans to file an NDA application for ASP 001 for the treatment of erectile dysfunction (ED) in the US
- 31 Jul 2024 Efficacy data from a phase I trial in Erectile Dysfunction released by Aspargo Labs
- 01 Dec 2023 Aspargo Laboratories completes enrollment in a phase I pharmacokinetic/bioequivalence trial for Erectile dysfunction